Pyxis Oncology, Inc. Operating Cash Flow
Pyxis Oncology, Inc. (PYXS) reported Operating Cash Flow of -$44.21 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Pyxis Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$18.21M.
- Pyxis Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$26.00M.
- Pyxis Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$10.43M.
- Pyxis Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$13.28M.
- Pyxis Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$63.50M.
- Pyxis Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$57.67M.
- Pyxis Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$70.71M.
- Pyxis Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$89.33M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$18.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$44.21M 10-Q · filed 2026-08-13 | -$54.63M derived: sum of 3 quarters · filed 2026-08-13 | -$67.91M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$26.00M 10-Q · filed 2026-05-14 | -$36.43M derived: sum of 2 quarters · filed 2026-05-14 | -$49.70M derived: sum of 3 quarters · filed 2026-05-14 | -$66.97M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$10.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$23.70M derived: sum of 2 quarters · filed 2026-03-23 | -$40.97M derived: sum of 3 quarters · filed 2026-08-13 | -$63.50M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$13.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$30.54M derived: sum of 2 quarters · filed 2026-08-13 | -$53.08M 10-Q · filed 2025-11-03 | -$72.36M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$17.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$39.80M 10-Q · filed 2026-08-13 | -$59.09M derived: sum of 3 quarters · filed 2026-08-13 | -$73.75M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$22.54M 10-Q · filed 2026-05-14 | -$41.83M derived: sum of 2 quarters · filed 2026-05-14 | -$56.49M derived: sum of 3 quarters · filed 2026-05-14 | -$59.50M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$19.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$33.95M derived: sum of 2 quarters · filed 2026-03-23 | -$36.96M derived: sum of 3 quarters · filed 2026-03-23 | -$57.67M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$14.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | -$17.67M derived: sum of 2 quarters · filed 2025-11-03 | -$38.38M 10-Q · filed 2025-11-03 | -$53.64M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$23.72M 10-Q · filed 2025-08-14 | -$38.97M derived: sum of 3 quarters · filed 2025-08-14 | -$56.55M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$20.71M 10-Q · filed 2025-05-15 | -$35.96M derived: sum of 2 quarters · filed 2025-05-15 | -$53.55M derived: sum of 3 quarters · filed 2025-05-15 | -$64.58M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$15.25M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$32.84M derived: sum of 2 quarters · filed 2025-03-18 | -$43.87M derived: sum of 3 quarters · filed 2025-03-18 | -$70.71M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$17.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$28.61M derived: sum of 2 quarters · filed 2024-11-12 | -$55.45M 10-Q · filed 2024-11-12 | -$72.84M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$11.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$37.87M 10-Q · filed 2024-08-14 | -$55.26M derived: sum of 3 quarters · filed 2024-08-14 | -$75.82M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$26.84M 10-Q · filed 2024-05-14 | -$44.23M derived: sum of 2 quarters · filed 2024-05-14 | -$64.78M derived: sum of 3 quarters · filed 2024-05-14 | -$88.50M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$17.39M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$37.94M derived: sum of 2 quarters · filed 2024-03-21 | -$61.66M derived: sum of 3 quarters · filed 2024-03-21 | -$89.33M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$20.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$44.27M derived: sum of 2 quarters · filed 2023-11-07 | -$71.95M 10-Q · filed 2023-11-07 | -$84.12M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$23.71M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$51.39M 10-Q · filed 2023-08-11 | -$63.56M derived: sum of 3 quarters · filed 2023-08-11 | -$70.85M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$27.68M 10-Q · filed 2023-05-11 | -$39.85M derived: sum of 2 quarters · filed 2023-05-11 | -$47.14M derived: sum of 3 quarters · filed 2023-05-11 | -$44.27M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$12.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | -$19.46M derived: sum of 2 quarters · filed 2023-03-22 | -$16.59M derived: sum of 3 quarters · filed 2023-03-22 | -$35.33M 10-K · filed 2023-03-22 |
| 2021-09-30 | -$7.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$4.43M derived: sum of 2 quarters · filed 2022-11-01 | -$23.16M 10-Q · filed 2022-11-01 | -$26.32M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $2.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | -$15.87M 10-Q · filed 2022-08-15 | -$19.04M derived: sum of 3 quarters · filed 2022-08-15 | |
| 2021-03-31 | -$18.73M 10-Q · filed 2022-05-13 | -$21.90M derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | -$3.17M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$10.08M 10-K · filed 2022-03-29 | ||
| 2020-09-30 | -$6.92M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |